Help JNS get the facts out

The Wire


FDA-approved Zida Control Sock now available for sale in the US

A wearable neuromodulation device proven to treat the symptoms of over-active bladder, incontinence and urinary frequency and urgency provides a new non-invasive, home-use treatment option that can replace or compliment commonly prescribed pharmaceuticals.

In a recent clinical study, Zida’s patented device was 80% effective in treating symptoms of over-active bladder, with 71%reduction in episodes of incontinence and 62 percent reduction in episodes of urgency.

Zida’s non-invasive therapy option is easy-to-use and is easy to use. A Zida product video states that “if you can put on your socks in the morning and use your car’s key FOB, then you can use the Zida Control Sock.”

Similarly, Zida provides a new option for general practitioners to achieve meaningful results for their patients. The Zida device can either be used as a stand-alone treatment option or in conjunction with standard first- and second-line therapies like medication and/or behavioral education.

According to Dr. Martin Madorsky, a former chief of urology at South Miami Hospital and Baptist Hospital of Miami, past president of the Greater Miami Urological Society, currently practicing at the Urology Center of South Florida, “The Zida Wearable Neuromodulation system provides a more convenient therapy option for OAB that does not require frequent office visits or surgery.” He adds that this non-invasive treatment “closes a gap in the market” that is otherwise dominated by practice-based neuromodulation devices or other pharmaceutical options.

Elizabeth Chapman Shaid, an advanced practice nurse practitioner specializing in care of older adults, says, “The ability to prescribe the Zida device in conjunction with continued first-line pharmaceuticals has the ability to provide synergistic improvements that dramatically improve long-term patient satisfaction and outcomes.”

Isaac Oppenheim, CEO of Zida Therapuetics, says, “Patients are finding it much simpler to treat OAB with effective neuromodulation therapy at home, rather than making a dozen visits to the doctor’s office.  The synergy between the Zida Control Sock System and Zidafy platform will exponentially increase the number of patients able to get to 100% improvements in their symptoms. It is our mission to bring the OAB market into the 21st century.”

In product trials, patients have been impressed with the results. According to Kim, age 57, “Since using the Zida sock I feel more confident that I can make it to the bathroom, so I am less hurried. At night when it is physically harder for me to get up, I have found I can get to my commode without urinating on the floor or myself. I also find that I urinate less often.”

Juanita, age 65, says that she “appreciates the difference the sock has made,” adding that “I have less urgencies, less of those running-in-the-house accidents, and less ‘DEPENDS.’”

Visit to learn more about the device, speak with an incontinence specialist and see if the product is right for you.

About & contact The Publisher
Zida is the exclusive worldwide distributor of the Zida Wearable Neuromodulation system. Zida Therapeutics team includes world-leading practitioners of neuromodulation, paired with successful entrepreneurs who have significant product development, marketing and financial management experience. Zida is focused on making 100% patient symptom improvement a reality.
Releases published on the JNS Wire are communicated and paid for by third parties. Jewish News Syndicate, and any of its distribution partners, take zero responsibility for the accuracy of any content published in any press release. All the statements, opinions, figures in text or multimedia including photos or videos included in each release are presented solely by the sponsoring organization, and in no way reflect the views or recommendation of Jewish News Syndicate or any of its partners. If you believe any of the content in a release published on JNS Wire is offensive or abusive, please report a release.
Never miss a thing
Get the best stories faster with JNS breaking news updates